IgM multiple myeloma: diagnostic difficulties and results of bortezomib treatment – case report
Journal Title: OncoReview - Year 2014, Vol 4, Issue 4
Abstract
The IgM paraprotein secretion is most frequently associated with Waldenström’s macroglobulinemia. In very rare cases it may also occur in multiple myeloma. The diagnostic and therapeutic process of a 84 year old male suffering from IgM multiple myeloma is described, including difficulties in establishing this diagnosis. Due to infectious complications, after the first cycle of melphalan–prednisone–bortezomib treatment, melphalan was stopped, subsequently, bortezomib and prednisone doses were also reduced. Two treatment interruptions have occurred. Despite reduced treatment intensity, the patient was in very good partial remission, while the toxicity profile was acceptable.IgM multiple myeloma should be included in the differential diagnosis of IgM paraproteinemia, also when osteolytic lesions and translocation 11:14 are not detected. Bortezomib-based therapy can be effective in elderly patients (also in those suffering from cardiac insufficiency), even when dose reduction is required.
Authors and Affiliations
Rafał Machowicz, Kamila Skwierawska, Krzysztof Mądry, Michał Górka, Jagoda Żurawska, Piotr Kacprzyk, Anna Waszczuk-Gajda, Jadwiga Dwilewicz-Trojaczek
Keywords
Related Articles
- EP ID EP67769
- DOI -
- Views 234
- Downloads 0
Cardiac Biomarkers and Early Detection of Cardiotoxicity
Rehabilitacja chorych na nowotwory układu oddechowego
Większość chorych na raka płuca ma współistniejącą przewlekłą obturacyjną chorobę płuc oraz chorobę serca. Zakres planowanego leczenia przeciwnowotworowego zawsze musi uwzględniać stan kardiologiczny i pneumonologiczny p...
Fertility and breast cancer
Breast cancer is the most common cancer among females worldwide. The mean age of breast cancer patients is > 60 yrs old, and it is seldom found in women < 40 yrs old (6.5%) and in very young women < 35 yrs old (0.6%). In...
The cardiac safety during treatment with sunitinib and sorafenib, multikinase angiogenesis inhibitors
Cardiotoxicity of multikinase angiogenesis inhibitors, sunitinib and sorafenib, is most often myocardial systolic dysfunction or arterial and venous thromboembolic events. Essential risk factor seems to be iatrogenic art...
„D-dimerosis” among the patients with the cancer it is always needed to be treated?
The risk of thromboembolic disease increases in malignant tumors. D-dimer is a product of fibrin degradation. Its concentration rises in neoplasms, but also in another diseases characterized by activation of clotting and...